Clinical Trial

A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily activities) decline. For each participant, the study will last one and a half years.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-18
Trial Details
NCT Number NCT07589595
Lead Sponsor Eli Lilly and Company
Conditions Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
Enrollment 350 participants
Start Date 2026-05-20
Primary Completion 2028-08 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-08-06